{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/management/general-management/","result":{"pageContext":{"chapter":{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management","depth":2,"htmlHeader":"<!-- begin field f9cc18d3-43bb-4b87-9d44-9ab9e05f7056 --><h2>Scenario: General management</h2><!-- end field f9cc18d3-43bb-4b87-9d44-9ab9e05f7056 -->","summary":"Covers the primary care management of people with confirmed multiple sclerosis.","htmlStringContent":"<!-- begin item 020d9213-c407-4492-aeee-d8d7e86ca4be --><!-- begin field 8eb4cb99-4ef3-4e62-927f-acbc0157523b --><p>From age 18 years onwards.</p><!-- end field 8eb4cb99-4ef3-4e62-927f-acbc0157523b --><!-- end item 020d9213-c407-4492-aeee-d8d7e86ca4be -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4842adfc-812a-5997-9cf7-cc35f3db0bbf","slug":"general-management","fullItemName":"General management","depth":3,"htmlHeader":"<!-- begin field 62e4d53c-51e9-477d-8758-f2235a720672 --><h3>How should I manage someone with confirmed multiple sclerosis?</h3><!-- end field 62e4d53c-51e9-477d-8758-f2235a720672 -->","summary":null,"htmlStringContent":"<!-- begin item 9c310e35-b165-4a23-8e49-d258a206cf4c --><!-- begin field dc5e0f40-8447-4024-8396-7957b2e0901f --><ul><li><strong>If a diagnosis of multiple sclerosis (MS) is confirmed:</strong><ul><li>The person should be under the care of a consultant neurologist and a multidisciplinary MS team.</li><li>Specialist MS nurses have a key role within the team and are a vital link between primary care, secondary care, and community services. They are often the first point of contact for people with MS and provide advice and support for management of relapses and other MS-related problems.</li></ul></li><li><strong>Offer lifestyle advice to promote general good health — advice is no different to health promotion for all people, but in particular:</strong><ul><li>Encourage regular exercise — this may have beneficial effects for people with MS.</li><li>Advise smokers to stop smoking — smoking may increase progression of disability.</li><li>Ensure optimal management of comorbid conditions, such as depression, anxiety, and vascular risk factors — these are associated with worse outcomes in people with MS. Be aware that some medications may interact with disease-modifying therapies for MS.</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>, <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li></ul></li><li><strong>Be aware that live vaccinations may be contraindicated in people with MS who are being treated with disease-modifying therapies — seek specialist advice.</strong><ul><li>Flu vaccinations should be offered to people with MS in line with national guidance. The possible risk of relapse after flu vaccination should be discussed if the person has relapsing-remitting MS.</li></ul></li><li><strong>In women who are pregnant or planning a pregnancy:</strong><ul><li>Relapse rates may reduce during pregnancy and may increase 3–6 months postpartum before returning to pre-pregnancy rates.</li><li>Pregnancy does not increase the risk of disease progression.</li></ul></li><li><strong>If a person with MS is considering pregnancy, ensure they have discussed this with their specialist team who will provide advice on:</strong><ul><li>Fertility.</li><li>The risk of the child developing MS.</li><li>Use of vitamin D before conception and during pregnancy.</li><li>Medication use in pregnancy — some disease-modifying therapies are contraindicated in pregnancy and breastfeeding but risks associated with stopping treatment must also be considered.</li><li>Pain relief during delivery (including epidurals).</li><li>Care of the child including breastfeeding.</li></ul></li><li><strong>If a woman with MS becomes pregnant, ensure that the MS team are notified as soon as possible so that appropriate support and liaison with the obstetric team can be arranged.</strong><ul><li>Urinary tract infections are more frequent in women with MS during pregnancy — provide information on recognition of symptoms and advise them to seek prompt treatment if concerned.</li><li>Be aware that there is an increased risk of postpartum depression in mothers and fathers with MS — ensure appropriate management.</li></ul></li><li><strong>Offer information about MS including:</strong><ul><li>Details of patient organizations that provide information on symptomatic, psychological, and social aspects of living with MS, such as:<ul><li>The MS Trust (<a href=\"http://www.mstrust.org.uk/\" data-hyperlink-id=\"8e87385a-2508-4e71-9900-ac2100e15119\">www.mstrust.org.uk</a>).</li><li>The MS Society (<a href=\"http://www.mssociety.org.uk/\" data-hyperlink-id=\"19d384e4-b673-4273-a1d8-ac2100e15152\">www.mssociety.org.uk</a>).</li></ul></li><li>Legal requirements such as notifying the Driver and Vehicle Licensing Agency (DVLA).<ul><li>Detailed information is available in the DVLA document <a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/866655/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"553a76c2-7f95-48dc-9002-ac2c00c599a9\">Assessing fitness to drive - a guide for medical professionals</a>.</li><li>Legal rights including social care, employment rights, and benefits — ensure the social care needs of the person with MS and their family/carers have been met and refer to social services where appropriate.</li></ul></li></ul></li><li><strong>Ensure that the person has a comprehensive review of all aspects of their care at least once a year.</strong><ul><li>This is usually arranged and carried out in secondary care. However, during any consultation with a person with MS, it is prudent to check that review has taken place in the preceding 12 months.</li></ul></li><li><strong>When appropriate:</strong><ul><li>Discuss the possibility that MS might lead to cognitive problems and the importance of regular assessment to identify and address problems.</li><li>Provide information on advance care planning and power of attorney to the person with MS (and their family members or carers if the person wishes) — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a>.</li><li>Manage symptoms and end of life care in conjunction with the MS team and palliative care services – for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care – general issues</a>.</li></ul></li></ul><!-- end field dc5e0f40-8447-4024-8396-7957b2e0901f --><!-- end item 9c310e35-b165-4a23-8e49-d258a206cf4c -->","subChapters":[{"id":"159ad434-08bc-55ae-9d88-50aed2aedd93","slug":"basis-for-recommendation-326","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ba4ebf9c-8e97-4990-b803-8e8b731f6372 --><h4>Basis for recommendation</h4><!-- end field ba4ebf9c-8e97-4990-b803-8e8b731f6372 -->","summary":null,"htmlStringContent":"<!-- begin item 326f7adb-5d40-496f-b1cd-2038b9fa4ec8 --><!-- begin field 6998b595-9212-4ee5-9bbb-72c06bab7e48 --><p class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">The recommendations on the general management of multiple sclerosis (MS) in primary care are based on clinical guidelines <em style=\"mso-bidi-font-style: normal;\">Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Scolding, 2015</a>], <em style=\"mso-bidi-font-style: normal;\">Recommendations for cognitive screening and management in multiple sclerosis care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Kalb, 2018</a>], <em style=\"mso-bidi-font-style: normal;\">Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Rae-Grant, 2018</a>], <em style=\"mso-bidi-font-style: normal;\">UK consensus on pregnancy in multiple sclerosis: the Association of British Neurologists' guidelines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019a</a>], <em style=\"mso-bidi-font-style: normal;\">Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Farez, 2019</a>], <em style=\"mso-bidi-font-style: normal;\">Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>], <em>EAN guideline on palliative care of people with severe, progressive multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Solari, 2020</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Hassan-Smith, 2011b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Galea, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Halabchi, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</p><h5 class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">Lifestyle advice and information</h5><ul><li class=\"MsoNormal\">Recommendations on primary prevention including encouraging people with MS to take regular exercise and to stop smoking (where appropriate) are based on the National Institute for Health and Care Excellence (NICE) guideline <em style=\"mso-bidi-font-style: normal;\">Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Hernan, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Hedstrom, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Pittas, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Halabchi, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Rae-Grant, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>]. The recommendation about smoking is in keeping with studies that have shown that smoking roughly doubles the risk of developing MS, and may adversely affect the disease course. </li><li class=\"MsoNormal\">The recommendation on optimal management of comorbid conditions, such as mental health problems, and cardiovascular risk factors, such as obesity, hypertension, diabetes mellitus, and high cholesterol, are based on expert opinion in a clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Rae-Grant, 2018</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</li><li>The NICE guideline also states 'offer people suspected of having MS information about support groups and national charities'.</li></ul><h5 class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">Vaccination</h5><ul><li class=\"MsoNormal\">The recommendations on vaccination in people with MS are based on clinical guidance from the American Academy of Neurology <em style=\"mso-bidi-font-style: normal;\">Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Farez, 2019</a>] and NICE <em style=\"mso-bidi-font-style: normal;\">Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li></ul><h5 class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">Pregnancy</h5><ul><li class=\"MsoNormal\">The recommendations on pre-conception counselling and pregnancy are based on clinical guidelines <em style=\"mso-bidi-font-style: normal;\">Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Rae-Grant, 2018</a>], <em>UK consensus on pregnancy in multiple sclerosis: the Association of British Neurologists' guidelines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019a</a>], and <em style=\"mso-bidi-font-style: normal;\">Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li></ul><ul><li class=\"MsoNormal\">In some cases, delay of treatment in women with MS until they have completed their families can lead to development of irreversible disability. Although evidence is limited, it is important to discuss family planning and pregnancy proactively [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019a</a>].</li></ul><h5 class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">Comprehensive annual review</h5><ul><li class=\"MsoNormal\">The recommendation on annual review is based on the <em style=\"mso-bidi-font-style: normal;\">Association of British Neurologists</em>: <em style=\"mso-bidi-font-style: normal;\">revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Scolding, 2015</a>] and the NICE guidelines <em>Multiple</em><em style=\"mso-bidi-font-style: normal;\"> sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li></ul><h5 class=\"MsoNormal\" style=\"margin-left: 18.0pt;\">Social care needs and advance care planning</h5><ul><li class=\"MsoNormal\">Recommendations on social care needs and advance care planning are based on clinical guidelines <em style=\"mso-bidi-font-style: normal;\">Recommendations for cognitive screening and management in multiple sclerosis care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Kalb, 2018</a>], <em style=\"mso-bidi-font-style: normal;\">Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>], and the <em>EAN guideline on palliative care of people with severe, progressive multiple sclerosis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Solari, 2020</a>].</li></ul><!-- end field 6998b595-9212-4ee5-9bbb-72c06bab7e48 --><!-- end item 326f7adb-5d40-496f-b1cd-2038b9fa4ec8 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}